Acadia Pharmaceuticals INC Form 4 insider transactions

Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals, sold shares to cover withholding taxes related to vesting restricted stock units.

Director Adora Ndu reports acquisition and disposal of common stock and derivative securities in Acadia Pharmaceuticals.

Director Elizabeth A. Garofalo reports stock transactions, including the vesting of restricted stock units and stock option grants, in a recent SEC Form 4 filing.

Director James M. Daly of Acadia Pharmaceuticals reports acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options.

Director Edmund Harrigan reports the vesting and disposition of restricted stock units and the grant of stock options in Acadia Pharmaceuticals.

Director Daniel B. Soland reports acquisition and disposal of Acadia Pharmaceuticals stock and derivative securities.

Director Laura Brege reports acquisition and vesting of restricted stock units and stock options in Acadia Pharmaceuticals.

Baker Bros. Advisors and related entities report transactions involving Acadia Pharmaceuticals stock, including acquisitions of restricted stock units and stock options, as well as pro rata distributions.

Mark Schneyer, EVP and CFO of Acadia Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

EVP, COO, and Head of Commercial Brendan Teehan of Acadia Pharmaceuticals reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Principal Accounting Officer James Kihara of Acadia Pharmaceuticals reports acquisition and disposal of common stock and restricted stock units.

CEO Stephen Davis of Acadia Pharmaceuticals reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

CEO of Acadia Pharmaceuticals, Stephen Davis, reports the acquisition and disposal of common stock and restricted stock units.

EVP, COO, and Head of Commercial Brendan Teehan of Acadia Pharmaceuticals reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, reports acquisition and disposal of common stock and restricted stock units to cover withholding taxes.

Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals, sold shares to cover withholding taxes related to vesting restricted stock units.

James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

EVP, COO, and Head of Commercial Brendan Teehan reports acquisition and disposal of Acadia Pharmaceuticals stock and stock options.

CEO Stephen Davis of Acadia Pharmaceuticals reports acquisition and disposal of company stock related to vesting of performance stock units and tax obligations.

Mark Schneyer, EVP and CFO of Acadia Pharmaceuticals, reports acquisition and disposal of company stock and derivative securities.

Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals, reported the sale of 772 shares of common stock to cover withholding taxes related to the vesting of restricted stock units.

EVP, COO, and Head of Commercial Brendan Teehan of Acadia Pharmaceuticals reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Acadia Pharmaceuticals CEO Stephen Davis reports the acquisition of 10,946 shares of common stock through restricted stock unit vesting and the sale of 5,577 shares to cover withholding taxes.